Evaluation of a self-nanoemulsifying docetaxel delivery system

Biomed Pharmacother. 2019 Jan:109:2427-2433. doi: 10.1016/j.biopha.2018.11.110. Epub 2018 Nov 30.

Abstract

A self-nanoemulsifying drug delivery system (SNEDDS) was developed as a novel route to enhance the efficacy of docetaxel lipophilic drug. SNEDDS comprised ethyl oleate, Tween 80 and poly(ethylene glycol) 600, as oil, surfactant and co-surfactant, and formed stabilized monodispersed oil nanodroplets upon dilution in water. SNEDDS represented encapsulation efficiency and loading capacity of 21.4 and 52.7%, respectively. The docetaxel release profile from the drug-loaded SNEDDS was recorded, its effectiveness against MCF-7 cell line was investigated, and an IC50 value of 0.98 ± 0.05 μg mL-1 was attained. The drug-loaded SNEDDS was administrated in rats, and the pharmacokinetic parameters of maximum concentration of 22.2 ± 0.8 μg mL-1, time to attain this maximum concentration of 230 min, and area under the curve of 1.71 ± 0.18 μg min mL-1 were obtained. The developed SNEDDS formulation can be represented as an alternative to docetaxel administration.

Keywords: Anticancer drug; Breast cancer; MCF7 cell; Nanoemulsion; Taxotere.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Cell Survival / drug effects*
  • Cell Survival / physiology
  • Docetaxel / administration & dosage*
  • Docetaxel / pharmacokinetics
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems / methods*
  • Drug Evaluation, Preclinical / methods
  • Emulsifying Agents / administration & dosage*
  • Emulsifying Agents / pharmacokinetics
  • Female
  • Humans
  • MCF-7 Cells
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antineoplastic Agents
  • Emulsifying Agents
  • Docetaxel